Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Background: Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial. Objective: The objective of this paper is to present efficacy and safety results in A...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2026-04-01
Seri Bilgileri:	The Journal of Prevention of Alzheimer's Disease
Konular:	Lecanemab Alzheimer’s disease Apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S2274580726000312
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Benzer Materyaller